Peptide Library

FDA-approved

Hormones & metabolism

Somapacitan

Evidence

FDA approved

Class

Long-acting growth hormone

/

Somapacitan

KEY TAKEAWAY

Somapacitan is a growth hormone analog modified with an albumin-binding side chain so that it lasts about a week. It is sold as Sogroya. The FDA approved somapacitan (Sogroya) in 2020 for adults with growth hormone deficiency and in 2023 for children.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Long-acting growth hormone

Approved for

Growth hormone deficiency in children and adults

Key fact

The FDA approved somapacitan (Sogroya) in 2020 for adults with growth hormone deficiency and in 2023 for children.

Route

Weekly subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Somapacitan is a growth hormone analog modified with an albumin-binding side chain so that it lasts about a week. It is sold as Sogroya.

How it works

How it works

It activates growth hormone receptors, which raises IGF-1 and promotes growth and healthy body composition.

Regulatory status

Regulatory status

The FDA approved somapacitan (Sogroya) in 2020 for adults with growth hormone deficiency and in 2023 for children.

What it is used for

What it is used for

Growth hormone deficiency in children and adults.

Side effects and risks

Side effects and risks

Headache, injection-site reactions and joint pain are common. Higher blood sugar is possible.

Citations

Citations

U.S. FDA prescribing information for Somapacitan. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo